JP2018039853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018039853A5 JP2018039853A5 JP2017242759A JP2017242759A JP2018039853A5 JP 2018039853 A5 JP2018039853 A5 JP 2018039853A5 JP 2017242759 A JP2017242759 A JP 2017242759A JP 2017242759 A JP2017242759 A JP 2017242759A JP 2018039853 A5 JP2018039853 A5 JP 2018039853A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- lymphoma
- antigen
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000012642 immune effector Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 238000009169 immunotherapy Methods 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 239000000439 tumor marker Substances 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 102100029951 Estrogen receptor beta Human genes 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 claims 1
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 102100039648 Lactadherin Human genes 0.000 claims 1
- 102000002297 Laminin Receptors Human genes 0.000 claims 1
- 108010000851 Laminin Receptors Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 102100020872 Leucyl-cystinyl aminopeptidase Human genes 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 1
- 101710114878 Phospholipase A-2-activating protein Proteins 0.000 claims 1
- 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 claims 1
- 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 108060008724 Tyrosinase Proteins 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 101710145727 Viral Fc-gamma receptor-like protein UL119 Proteins 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 229960001445 alitretinoin Drugs 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
- 229960004961 mechlorethamine Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 229940086322 navelbine Drugs 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- -1 pricamycin (pomycin) Chemical compound 0.000 claims 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 1
- 229960000624 procarbazine Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 229960004622 raloxifene Drugs 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000005630 sialyl group Chemical group 0.000 claims 1
- 101150047061 tag-72 gene Proteins 0.000 claims 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical group C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18951108P | 2008-08-20 | 2008-08-20 | |
| US61/189,511 | 2008-08-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016191062A Division JP6315841B2 (ja) | 2008-08-20 | 2016-09-29 | 有機ヒ素化合物および癌を処置するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018039853A JP2018039853A (ja) | 2018-03-15 |
| JP2018039853A5 true JP2018039853A5 (https=) | 2018-06-14 |
Family
ID=41707414
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523888A Active JP5933896B2 (ja) | 2008-08-20 | 2009-08-14 | 有機ヒ素化合物および癌を処置するための方法 |
| JP2014108079A Active JP5976036B2 (ja) | 2008-08-20 | 2014-05-26 | 有機ヒ素化合物および癌を処置するための方法 |
| JP2015068284A Withdrawn JP2015120755A (ja) | 2008-08-20 | 2015-03-30 | 有機ヒ素化合物および癌を処置するための方法 |
| JP2016191062A Active JP6315841B2 (ja) | 2008-08-20 | 2016-09-29 | 有機ヒ素化合物および癌を処置するための方法 |
| JP2017242759A Pending JP2018039853A (ja) | 2008-08-20 | 2017-12-19 | 有機ヒ素化合物および癌を処置するための方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523888A Active JP5933896B2 (ja) | 2008-08-20 | 2009-08-14 | 有機ヒ素化合物および癌を処置するための方法 |
| JP2014108079A Active JP5976036B2 (ja) | 2008-08-20 | 2014-05-26 | 有機ヒ素化合物および癌を処置するための方法 |
| JP2015068284A Withdrawn JP2015120755A (ja) | 2008-08-20 | 2015-03-30 | 有機ヒ素化合物および癌を処置するための方法 |
| JP2016191062A Active JP6315841B2 (ja) | 2008-08-20 | 2016-09-29 | 有機ヒ素化合物および癌を処置するための方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20110269697A1 (https=) |
| EP (2) | EP2321012B1 (https=) |
| JP (5) | JP5933896B2 (https=) |
| KR (3) | KR20180103194A (https=) |
| CN (2) | CN104800828A (https=) |
| AU (1) | AU2009282972A1 (https=) |
| BR (1) | BRPI0918407A2 (https=) |
| CA (1) | CA2734650A1 (https=) |
| DK (2) | DK2321012T3 (https=) |
| ES (2) | ES2703740T3 (https=) |
| HK (1) | HK1212218A1 (https=) |
| IL (1) | IL211153A0 (https=) |
| MX (1) | MX2011001800A (https=) |
| NZ (1) | NZ591181A (https=) |
| PT (2) | PT3388111T (https=) |
| RU (1) | RU2534606C2 (https=) |
| SG (3) | SG10201810450QA (https=) |
| WO (1) | WO2010021928A1 (https=) |
| ZA (1) | ZA201101216B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI617305B (zh) * | 2013-12-05 | 2018-03-11 | 蘇愛康制藥有限公司 | 治療癌症的化合物及其應用程序 |
| CN104151397A (zh) * | 2014-07-03 | 2014-11-19 | 北京大学 | 一类新型三硫杂二环有机砷化物及其合成方法和在抗肿瘤领域里的应用 |
| JP6413969B2 (ja) * | 2015-07-29 | 2018-10-31 | 住友金属鉱山株式会社 | 日射遮蔽体形成用分散液および当該分散液を用いた日射遮蔽体 |
| JPWO2019220961A1 (ja) * | 2018-05-18 | 2020-05-28 | ソレイジア・ファーマ株式会社 | ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤 |
| US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
| CN113408945B (zh) * | 2021-07-15 | 2023-03-24 | 广西中烟工业有限责任公司 | 一种烤烟纯度的检测方法、装置、电子设备及存储介质 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US234972A (en) | 1880-11-30 | William ennis | ||
| US761900A (en) | 1904-03-05 | 1904-06-07 | Newton Jefferson Norman | Flux compound. |
| US2349729A (en) | 1940-08-24 | 1944-05-23 | Parke Davis & Co | Therapeutic arsenic preparation |
| JP2001519366A (ja) | 1997-10-15 | 2001-10-23 | ポーラクス バイオファーマシュティカルズ，インコーポレーテッド | ヒ素化合物を用いた、原発性および転移性の腫瘍性疾患を治療するための組成物および方法 |
| IL136051A0 (en) | 1997-11-10 | 2001-05-20 | Sloan Kettering Inst Cancer | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| CN1233476A (zh) | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| EP1002537A1 (en) | 1998-10-30 | 2000-05-24 | Assistance Publique, Hopitaux De Paris | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma |
| US6191123B1 (en) | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
| EP1328253B1 (en) | 2000-04-26 | 2006-03-22 | Oregon Health Sciences University | Administration of a thiol-based chemoprotectant compound |
| DE10132625A1 (de) | 2001-07-05 | 2003-01-23 | Oce Printing Systems Gmbh | Verfahren, Computerprogrammprodukt und Gerätesystem zum visuellen Überprüfen von Bilddaten |
| US6911471B2 (en) * | 2002-01-07 | 2005-06-28 | The Texas A&M University System | S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| TWI411431B (zh) * | 2004-07-16 | 2013-10-11 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
| ES2532666T3 (es) | 2005-07-29 | 2015-03-30 | Solasia Pharma K.K. | Compuestos y métodos para el tratamiento del cáncer |
| WO2007082104A2 (en) * | 2006-01-13 | 2007-07-19 | The Texas A & M University System | Compounds and methods for the treatment of cancer |
| TW200829261A (en) | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
| CA2694983A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Treatments of b-cell proliferative disorders |
| US20090047243A1 (en) * | 2007-07-17 | 2009-02-19 | Richard Rickles | Combinations for the treatment of b-cell proliferative disorders |
| KR20100100835A (ko) * | 2007-11-02 | 2010-09-15 | 지오팜 온콜로지 인코포레이티드 | 유기 비소제와의 병용 요법 |
| WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
-
2009
- 2009-08-14 RU RU2011110392/14A patent/RU2534606C2/ru active
- 2009-08-14 KR KR1020187026317A patent/KR20180103194A/ko not_active Ceased
- 2009-08-14 ES ES09808635T patent/ES2703740T3/es active Active
- 2009-08-14 CN CN201410740427.5A patent/CN104800828A/zh active Pending
- 2009-08-14 AU AU2009282972A patent/AU2009282972A1/en not_active Abandoned
- 2009-08-14 SG SG10201810450QA patent/SG10201810450QA/en unknown
- 2009-08-14 US US13/059,176 patent/US20110269697A1/en not_active Abandoned
- 2009-08-14 EP EP09808635.8A patent/EP2321012B1/en active Active
- 2009-08-14 JP JP2011523888A patent/JP5933896B2/ja active Active
- 2009-08-14 DK DK09808635.8T patent/DK2321012T3/en active
- 2009-08-14 ES ES18174817T patent/ES2901426T3/es active Active
- 2009-08-14 DK DK18174817.9T patent/DK3388111T3/da active
- 2009-08-14 WO PCT/US2009/053858 patent/WO2010021928A1/en not_active Ceased
- 2009-08-14 SG SG10201403869TA patent/SG10201403869TA/en unknown
- 2009-08-14 MX MX2011001800A patent/MX2011001800A/es not_active Application Discontinuation
- 2009-08-14 SG SG10201810449XA patent/SG10201810449XA/en unknown
- 2009-08-14 NZ NZ591181A patent/NZ591181A/xx not_active IP Right Cessation
- 2009-08-14 KR KR1020177024240A patent/KR20170103023A/ko not_active Ceased
- 2009-08-14 PT PT181748179T patent/PT3388111T/pt unknown
- 2009-08-14 EP EP18174817.9A patent/EP3388111B1/en active Active
- 2009-08-14 CA CA2734650A patent/CA2734650A1/en not_active Abandoned
- 2009-08-14 KR KR1020117006250A patent/KR20110058818A/ko not_active Ceased
- 2009-08-14 BR BRPI0918407A patent/BRPI0918407A2/pt not_active Application Discontinuation
- 2009-08-14 CN CN2009801356542A patent/CN102149432A/zh active Pending
- 2009-08-14 PT PT09808635T patent/PT2321012T/pt unknown
-
2011
- 2011-02-10 IL IL211153A patent/IL211153A0/en unknown
- 2011-02-15 ZA ZA2011/01216A patent/ZA201101216B/en unknown
-
2014
- 2014-05-26 JP JP2014108079A patent/JP5976036B2/ja active Active
- 2014-10-27 US US14/524,586 patent/US10842769B2/en active Active
-
2015
- 2015-03-30 JP JP2015068284A patent/JP2015120755A/ja not_active Withdrawn
-
2016
- 2016-01-07 HK HK16100117.0A patent/HK1212218A1/xx unknown
- 2016-09-29 JP JP2016191062A patent/JP6315841B2/ja active Active
-
2017
- 2017-12-19 JP JP2017242759A patent/JP2018039853A/ja active Pending
-
2020
- 2020-10-15 US US17/071,435 patent/US11324713B2/en active Active
- 2020-10-15 US US17/071,623 patent/US11324714B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018039853A5 (https=) | ||
| Lian et al. | Checkpoint CD47 function on tumor metastasis and immune therapy | |
| Litzow et al. | How I treat T-cell acute lymphoblastic leukemia in adults | |
| Zanetta et al. | Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer | |
| Huang et al. | Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites | |
| Bukhari et al. | Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss | |
| Kuczynski et al. | Impact of chemical-induced mutational load increase on immune checkpoint therapy in poorly responsive murine tumors | |
| Winer et al. | A phase 1, first-in-human, dose-escalation study of MGD024, a CD123 x CD3 bispecific dart® molecule, in patients with relapsed or refractory CD123-positive (+) hematologic malignancies | |
| RU2014141365A (ru) | Способ введения противоопухолевого агента | |
| RU2020122083A (ru) | Способ снижения ототоксичности у педиатрических пациентов, получающих химиотерапию препаратами платины | |
| JP2022508935A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| Saso et al. | Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma | |
| JP2005527487A5 (https=) | ||
| Khurana et al. | Primary cutaneous T‐cell lymphoblastic lymphoma: case report and literature review | |
| Ammatuna et al. | Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis | |
| JP2017527551A5 (https=) | ||
| JP2009502971A5 (https=) | ||
| Epperla et al. | A New Target for Hodgkin Lymphoma-Camidanlumab Tesirine | |
| CN112741833A (zh) | 西达本胺及其衍生物的用途 | |
| Akce et al. | Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV‐Negative Relapsed Plasmablastic Lymphoma | |
| Huang et al. | Standard intensive chemotherapy is less effective and far more toxic than attenuated induction and post-induction regimen in elderly patients with acute myeloid leukemia | |
| Huang et al. | The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience | |
| Konig et al. | Is targeted therapy feasible in acute myelogenous leukemia? | |
| El-Hadaad et al. | Adjuvant pelvic radiotherapy vs. sequential chemoradiotherapy for high-risk stage I-II endometrial carcinoma | |
| Lee et al. | Mixed-phenotype acute leukemia treated with decitabine |